

Rec'd PCT/PTO

16 DEC 2002


10/070665

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE
STATEMENT**Docket Number
2653/56Application Number
10/070,665Filing Date
March 8, 2002Examiner
To Be AssignedArt Unit
To Be AssignedInvention Title
POLYSIALIC ACID-KLH CONJUGATE VACCINEInventor(s)
LIVINGSTON, et al.Commissioner
for Patents
Washington, D.C. 20231

I hereby certify that this correspondence is being hand-delivered to the United States Patent and Trademark Office, addressed to Commissioner for Patents, Washington, D.C. 20231 on

Date: December 16, 2002


Reg. No. 38,413


Joseph A. Coppola

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby bring the following references to the attention of the Examiner. The references are listed on the attached modified PTO form 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed, except as otherwise indicated on the modified PTO form 1449.

Dated: December 16, 2002

By:


Joseph A. Coppola (Reg. No. 38,413)KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449	ATTY. DOCKET NO. 2653/56	SERIAL NO. 10/070,665
	APPLICANT(S) LIVINGSTON, et al.	
	FILING DATE March 8, 2002	GROUP To be assigned

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	INVENTORS NAME

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO

OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Jain, Rakeshture K., "Barriers to Drug Delivery in Solid Tumors", <i>Scientific American</i> , (July 1994) 271(1):58-65
		Burgess WH, et al., "Possible Dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue", <i>J Cell Biol</i> , (November 1990) 111(5 Pt 1):2129-38
		Curti, Brendan D., "Physical barriers to drug delivery in tumors" <i>Critical Reviews in Oncology/Hematology</i> , (1993) 14:29-39
		Hartwell, Leland H. et al., "Integrating Genetic Approaches into the Discovery of Anticancer Drugs" <i>Science</i> , (November 1997) 278:1064-1068
		Spitler, Lynn E., et al., "Cancer Vaccines: The Interferon Analogy", <i>Cancer Biotherapy</i> , (1995) 10(1):1-3
		Ksesksmi, Y, et al., "Cancer "Vaccines": An Idea Whose Time Has Come?" <i>The Journal of NIH Research</i> , (January 1995) 7:46-49
		Gura Trisha, "Systems for Identifying New Drugs Are Often Faulty" <i>Science</i> , (November 1997) 278:1041-1042
		Boon, Thierry "Toward A Genetic Analysis of Tumor Rejection Antigens" <i>Advances in Cancer Research</i> , 58:177-211
		Helling, F., et al., "GD ₃ Vaccines for Melanoma: Superior Immunogenicity of Keyhole Limpet Hemocyanin Conjugate Vaccine" <i>Cancer Research</i> , (January 1994) 54:197-203
		Roth, Jurgen, et al., "Reexpression of poly(sialic acid) units of the neural cell adhesion molecule in Wilms tumor" <i>Proc. Natl. Acad. Sci.</i> , (May 1998) 85:2999-3003
		Jennings, H.J., et al., "Induction of Meningococcal Group B Polysaccharide-Specific IgG Antibodies in Mice By using an N-Propionylated B Polysaccharide-Tetanus Toxoid Conjugate Vaccine" <i>The Journal of Immunology</i> , (September 1986) 137(5):1708-1713
		Pon, R. A., "N-Propionylated Group B Meningococcal Polysaccharide Mimics a Unique Bactericidal Capsular Epitope in Group B Neisseria Meningitidis" <i>J. Exp. Med.</i> (June 1997) 185(11):1929-1938
		Livingston, P.O., "Approaches to Augmenting the Immunogenicity of Melanoma Gangliosides: From Whole Melanoma Cells to Ganglioside-KLH Conjugate Vaccines", <i>Immunological Reviews</i> (1995) 145:147-166.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	